SCHEMBL3821097

SCHEMBL3821097

COc1ccc(S(=O)(=O)N2CCN(C(C)c3nc(OC4CCCCC4)c4cc(F)ccc4n3)CC2)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.80
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 2/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
ALDH1A1 P00352 3/20 0.43
GBA1 P04062 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4D Q08499 1/20 0.42
HTT P42858 1/20 0.41
THRB P10828 1/20 0.41
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
PKLR P30613 1/20 0.40
RAB9A P51151 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
PTGDR Q13258 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3825565 0.99 CFTR (0.79) CFTRSMN1; SMN2KDM4EGAAMAPT
SCHEMBL29428909 0.89 CFTR (1.00) CFTRSMN1; SMN2KDM4EGAAMAPT
SCHEMBL3822809 0.89 CFTR (1.00) CFTRSMN1; SMN2KDM4EGAAMAPT
SCHEMBL3824415 0.88 CFTR (0.98) CFTRSMN1; SMN2KDM4EGAAMAPT
SCHEMBL3839480 0.87 CFTR (0.95) CFTRSMN1; SMN2KDM4EGAAMAPT
SCHEMBL3819492 0.85 CFTR (0.60) CFTRKDM4EGAAMAPTALDH1A1
SCHEMBL3821547 0.83 CFTR (0.57) CFTRKDM4EMAPTALDH1A1GBA1
SCHEMBL3825231 0.83 CFTR (0.87) CFTRSMN1; SMN2KDM4EGAAMAPT
SCHEMBL15457326 0.82 CFTR (0.86) CFTRSMN1; SMN2KDM4EGAAMAPT
SCHEMBL3822320 0.82 CFTR (0.86) CFTRSMN1; SMN2KDM4EGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 US disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 EP disclosed
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters CFTR, ABCB1, ABCC2 CFTR 1/4885SMN1; SMN2 4840/4885KDM4E 4337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.